Navigation Links
Diatherix Laboratories Releases First Clinically Available Test For Confirmation of The Swine Flu Virus
Date:5/7/2009

elopment of the Tem-PCR avian flu test for the Asian strain of H5N1 as well as a respiratory infection differentiation test used during the SARS outbreak in China. These tests played a significant role in preventing the spread of SARS and avian flu in Asia.

"Since the Diatherix test allows physicians to quickly differentiate H1N1 patients from those who have similar symptoms, infected patients can be provided proper antiviral therapy in a timely manner," said Dennis Grimaud, chief executive officer of Diatherix Laboratories. "A rapid confirmation of H1N1 patients can mitigate many of the negative economic and social impacts associated with infectious disease outbreaks. For example, if in 24 hours or less we could verify a suspected student was not infected with the H1N1 virus, this could prevent a school district from closing."

For information on using the Diatherix Tem-PCR test for the H1N1 virus, please visit the company's web site at www.diatherix.com or call (866) 656-1179.

Diatherix Laboratories Inc. is located in the Hudson-Alpha Institute for Biotechnology in Huntsville, Ala. Diatherix operates as an independent CLIA-certified clinical laboratory providing advanced multiplex molecular diagnostic services such as Tem-PCR to identify infectious disease to hospitals and the healthcare community. In addition to the H1N1 test, the company has testing panels for other respiratory infections, healthcare-associated infections and Staphylococcus. Diagnostic Network Alliance (DNA), with representative offices throughout the United States, is the exclusive US distributor for Diatherix Laboratory. DNA and Diatherix Laboratories share corporate administrative headquarters in Brentwood, Tenn.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Dennis Grimaud


SOURCE Diatherix Laboratories Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Vivek Y. Reddy, M.D., Joins The Mount Sinai Medical Center as Director of Electrophysiology Laboratories
2. Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu
3. College of American Pathologists Is Confident in U.S. Laboratories Ability to Respond to Influenza Outbreak
4. Healthy Life Laboratories Announces Hemoglobin A1c iPhone Application
5. IDEXX Laboratories Announces First Quarter Results
6. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
8. Getting Closer to Controlling Cancer Requires Funding More Laboratories and Commitment Beyond Two Years of New Stimulus, Weiner and Berg Assert in Denver Post Oped
9. BioReference Laboratories Partners With Sysmex America
10. IDEXX Laboratories to Release 2009 First Quarter Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...2 Holly Potter, vice president, Pu...agement for Kaiser Permanente, received the "PR Te...held at the National Press Club. ,, PR News,...nnovators and professionals who day in and day out...ce. The winners of this year,s program set the ben...
(Date:12/2/2009)...., Dec. 2 From more than 1,100 pho...ning, joy and peace, the LIFE Foundation has selec...d using the popular photo-sharing Web site flickr....ontage on the LIFE Foundation,s Web site at www.l...submitted one photo and a caption to Flickr.com du...
(Date:12/2/2009)...c. 2 US Farms, Inc. (Pin..., Nursery and Wellness products, is pleased to ann...ts at the Cook,sware A,faire in Oakland, Calif., a...or additional information, contact US Farms, Inc. ...it http://cookswareafaire.com ,, Victor Brand...
(Date:12/2/2009)...., Dec. 2 Watson Pharmac... the Federal Trade Commission (FTC) has accepted a...g to Watson,s pending acquisition of privately hel... the Hart Scott Rodino waiting period, thereby per... parties have now obtained all regulatory approval...
(Date:12/2/2009)...Red Cross also part of the Hewlett-Packard Company...2 The Hewlett-Packard C...lion this year to help fund American Red Cross dis...com/cgi-bin/prnh/20090108/RedCrossLOGO ) ,, Th...p Philippine communities affected by typhoons in S...
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3Health News:Wonders of Life Photo Contest Winners Announced 2Health News:Wonders of Life Photo Contest Winners Announced 3Health News:US Farms, Inc. Showcasing Aloe365(TM) Product Line at Cook'sware A'faire at Oakland Zoo 2Health News:Watson Receives FTC Clearance for Arrow Acquisition 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 2Health News:Hewlett-Packard Company Foundation Donates $1 Million for Red Cross Disaster Response 3
... exercisers. A new study in older adults finds tha...process by as much as 25 percent//. The faster...e infected. The results appear in a recent iss...ding to Charles Emery, a professor of psychology a...
... this may be due to genetic factors, according to ...ychiatry.// In the January issue of the journal, r...ession is higher in women than in men, where it is...depression in twins done to date. In addition, it ...
Only 75 per cent of Australian children eligible for free booster vaccine against pneumococcal disease got their shots before the program finished at the end of 2005, government figures show//. Th
...he hunting and killing of any wild birds. Turkish ...that the prohibition would continue// till Turkey ...he Eastern part of Turkey has seen two deaths due ...sis period. Agriculture and Rural Affairs Mini...
...here is a fear instilled by the disease among the ...h. But now scientist hopes that the disease can be...ermining the genes responsible to fight the diseas...ch done by the Universities of Oxford, KwaZulu-Nat...
...t and mortality rates through the launch of its ne... 72,000 babies die every year during delivery in t...iranjeevi, the government aims to bring the matern...nd births. The infant mortality rate at present is...
Other Medicine News:Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 2Health News:Wounds Heal 25% Faster In Older Adults Who Exercise Regularly 3
(Date:12/2/2009)...ecember 2 Cardio Vascula...per of advanced,cardiovascular surgery technology,...tors approved a one-for-three forward stock split,...o Vascular Medical Device shareholders. , ...ated date the stock,split will be payable and the ...
(Date:12/2/2009)...2 Roche (SIX: RO, ROG; O...s Food & Drug Administration (FDA) approved an...acid test, to screen source plasma in pools compri...lled the cobas® TaqScreen MPX Test for use on...tro test for the simultaneous, direct detection of...
(Date:12/2/2009)...., Dec. 2 Novartis announced today...tion on Tasigna® (nilotinib) 200 mg capsules ... the strength of the company,s hematology portfoli...w data, at the 51st American Society of Hematology...e company,s current therapies and investigational ...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 1American Medical Informatics Association 28AMIA 29 Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certifi 13045 2National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 1National Coalition of Mental Health Consumer Survivor Organizations Hires Director of Government Relations 51792 2Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 1Proposed Water Trust Fund Bill Would Provide Solid Foundation for Improvement 51788 2
...ene Activity and Metabolic,Enzymes Show How Cells ...zyme A, a Key Player in the Daily Biochemical Rout...2007 /PRNewswire/ -- Investigators at,St. Jude Chi...the,dynamic genetic and biochemical changes that m...le called Coenzyme A (CoA), a key,player in metabo...
...07 /PRNewswire/ -- DiObex,Inc., a privately- held...ent of therapeutics to treat metabolic diseases, t...902, a novel Cortisol,Synthesis Inhibitor. , In a ...bo-controlled trial, patients with type 2 diabetes..., pharmacokinetics and,activity of three dose leve...
Other Medicine Technology:Study Shows Metabolic Strategy of Stressed Cell 2Study Shows Metabolic Strategy of Stressed Cell 3Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3
Woodson Elevator
Henner Elevator
Tenzel Double-Ended Periosteal Elevator
DesMarres Lid Retractor
Medicine Products: